Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee votes 18-6 to recommend approval of the female sexual dysfunction drug contingent on a risk management plan, despite unease about modest efficacy and risks such as fainting.